A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

Inclusion Criteria: Part 1- Healthy Volunteers only: * Absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead Electrocardiogram (ECG), hematology, blood chemistry, serology and urinalysis * A Body Mass Index (BMI) between 18 to 30 kilograms per square meter (kg/m\^2) inclusive * Female participants must be either surgically sterile or post-menopausal for at least one year * For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm Part 2- Chronic HBV-infected participants only: * A BMI between 18 to 30 kg/m\^2 inclusive * Chronic Hepatitis B infection, defined as positive test for Hepatitis B surface antigen (HBsAg) for more than 6 months prior to randomization * HBV DNA at screening greater than or equal to (\>/=) 2 × 10\^4 international units per milliliter (IU/mL) for Hepatitis B e antigen (HBeAg) positive participants, or \>/=2 × 10\^3 IU/mL for HBeAg-negative participants * Liver biopsy, fibroscan or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic HBV infection with absence of extensive bridging fibrosis and absence of cirrhosis * For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm * For women of childbearing potential: agreement to remain abstinent or use non-hormonal contraceptive met…